Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.44 |
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1476149 | 0.86 | GPR119 (0.46) | HPGDGPR119FKBP1ARORCTACR1 | |
| SCHEMBL1475928 | 0.86 | GPR119 (0.46) | HPGDGPR119FKBP1ARORCTACR1 | |
| SCHEMBL1473792 | 0.86 | GPR119 (0.46) | HPGDGPR119FKBP1ARORCTACR1 | |
| SCHEMBL16987111 | 0.83 | OPRD1 (0.50) | GPR119TACR1OPRD1OPRK1MEN1 | |
| SCHEMBL1477603 | 0.83 | GPR119 (0.44) | HPGDGPR119FKBP1ARORCTACR1 | |
| SCHEMBL16987028 | 0.82 | PKM (0.46) | HPGDGPR119TACR1OPRD1OPRK1 | |
| SCHEMBL3592260 | 0.78 | TACR1 (0.49) | GPR119TACR1OPRD1OPRK1MAPT | |
| SCHEMBL3356420 | 0.78 | KDM1A (0.46) | RORCTACR1POLBMEN1KMT2A | |
| SCHEMBL3158101 | 0.77 | USP2 (0.46) | HPGDSMN1; SMN2MEN1KMT2AALOX15 | |
| SCHEMBL25343890 | 0.77 | RORC (0.45) | GPR119RORCTACR1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| CN-111454188-A | Cyclopropylamines as L SD1inhibitors | 因赛特公司 | 2020-07-28 | — | — | CN | disclosed |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-07-21 | — | — | US | disclosed |
| EP-3626713-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| US-9493442-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493442-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2015123465-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123465-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123408-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123408-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225379-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225379-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HPGD 869/4885GPR119 1776/4885FKBP1A 196/4885 |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | HPGD 869/4885GPR119 1776/4885FKBP1A 196/4885 |
| US-20150225379-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HPGD 869/4885GPR119 1776/4885FKBP1A 196/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | HPGD 869/4885GPR119 1776/4885FKBP1A 196/4885 |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | HPGD 869/4885GPR119 1776/4885FKBP1A 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.